Balik, M.
Kosina, J.
Husek, P.
Pacovsky, J.
Brodak, M.
Cecka, F.
Funding for this research was provided by:
Univerzita Karlova v Praze (PROGRES Q40/04)
Article History
Received: 18 July 2021
Accepted: 4 June 2022
First Online: 18 June 2022
Declarations
:
: This trial was approved by the independent ethics committee at the University Hospital Hradec Kralove (registration number 201903 I90P). The RARPEX trial will be conducted in the context of Good Clinical Practice and in accordance with the Declaration of Helsinki. All patients who are scheduled for robotic-assisted radical prostatectomy in our institutions will be screened for eligibility and informed in detail about the RARPEX trial. Informed consent will be obtained from each participant. The study procedures, risks, benefits, and data management will be clarified with the patients before they are asked to give their informed consent to participate. Any participant in this study may withdraw consent or voluntarily cease to participate at any time for any reason.
: Not applicable.
: The authors declare that they have no competing interests.